I'm considering investing in CGS after researching the company and I like what I see but I'm just unsure about one thing.
Can any investors with a deeper knowledge of the business comment on whether the ability to detect Alzheimers using a blood test have a detrimental effect on CGS's operations?
Could this mean less assessments using CGS tests?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
0.005(0.29%) |
Mkt cap ! $293.0M | |||
| Open | High | Low | Value | Volume |
| $1.70 | $1.79 | $1.70 | $167.4K | 96.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 887 | $1.74 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.77 | 1811 | 2 |
View Market Depth
| Last trade - 14.07pm 01/07/2025 (20 minute delay) ? |
| CGS (ASX) Chart |